- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01085149
The Effect Of Simvastatin On Bone Remodeling In Socket Of Mandibular Teeth
March 10, 2010 updated by: Hadassah Medical Organization
Simvastatin has been reported to promote osteoblastic activity and inhibit osteoclastic activity by enhancing the expression of BMP2.
There have been many studies demonstrating the bone-promoting effect of local application various animal models including after application into socket of teeth in a rat. the purpose of the study is to investigate the effect of slow release topical simvastatin in socket of mandibular teeth on bone remodeling in the socket
Study Overview
Detailed Description
after extraction of mandibular single root teeth 10 mg of slow release simvastatin would be inserted to the socket.
observation will be at 1 week, 4 weeks and 3 months.after
3 months the patients will have dental CT as done routinely in our clinic before placing dental implants and the bone density and height will be measured on this data.
during the procedure of inserting a dental implant a trephine will be taken for histology.
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Jerusalem, Israel, 91120
- Oral and Maxillofacial Clinic, Hadassah
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- need extraction of single root tooth
- intend to have prosthetic implant in place of extraction
Exclusion Criteria:
- treated with simvastatin P.O for hypercholesterolemia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: study group
simvastatin will be inserted to sockets
|
10 mg simvastatin, slow release in socket of extracted tooth (single application only)
|
|
No Intervention: control
sockets will be left to healing without material in socket
|
10 mg simvastatin, slow release in socket of extracted tooth (single application only)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
bone height and density in former socket
Time Frame: 3 months
|
measured on CT
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
bone mineralization
Time Frame: 3 months
|
histology from bone in former socket
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: casap nardi, MD, DMD, Hadassah Medical Organization
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2010
Primary Completion (Anticipated)
October 1, 2010
Study Registration Dates
First Submitted
March 10, 2010
First Submitted That Met QC Criteria
March 10, 2010
First Posted (Estimate)
March 11, 2010
Study Record Updates
Last Update Posted (Estimate)
March 11, 2010
Last Update Submitted That Met QC Criteria
March 10, 2010
Last Verified
March 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Lipid Metabolism Disorders
- Hyperlipidemias
- Dyslipidemias
- Hypercholesterolemia
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Simvastatin
Other Study ID Numbers
- h123-HMO-CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypercholesterolemia
-
National Medical Research Center for Therapy and...Moscow State University of Medicine and DentistryActive, not recruitingMedication Adherence | Adherence, Medication | Treatment Adherence | Familial Hypercholesterolemia | Motivational Interviewing | Adherence, Patient | Treatment Adherence and Compliance | Patient Compliance | Adherence | Hypercholesterolemia, Familial | Patient Adherence | Hypercholesterolemia, Autosomal Dominant and other conditionsRussian Federation
-
Institut Investigacio Sanitaria Pere VirgiliRecruitingFamilial Hypercholesterolemia | Familial Hypercholesterolemia - Homozygous | Familial Hypercholesterolemia - HeterozygousSpain
-
Direct PlantesUnknownHYPERCHOLESTEROLEMIAFrance
-
Novartis PharmaceuticalsNot yet recruitingDyslipidemia, Hypercholesterolemia
-
Shanghai General Hospital, Shanghai Jiao Tong University...Accuredit Therapeutics US LimitedNot yet recruitingHeterozygous Familial HypercholesterolemiaChina
-
Addpharma Inc.Not yet recruitingPrimary Hypercholesterolemia
-
Chong Kun Dang PharmaceuticalRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Shenzhen Salubris Pharmaceuticals Co., Ltd.Salubris (Chengdu) Biotechnology Co., Ltd.CompletedHypercholesterolemia and Mixed DyslipidemiaChina
-
Provident Clinical ResearchGlaxoSmithKlineCompletedPrimary HypercholesterolemiaUnited States
-
Addpharma Inc.CompletedPrimary HypercholesterolemiaKorea, Republic of
Clinical Trials on Simvastatin
-
University of CopenhagenCompletedCardiovascular Disease | Diabetes MellitusDenmark
-
Kafrelsheikh UniversityCompletedLiver Cirrhosis | Portal Hypertension Related to CirrhosisEgypt
-
dr.Frank L.J. VisserenMerck Sharp & Dohme LLCCompletedThe PostprAndial eNdothelial Function After Combination of Ezetimibe and simvAstatin Study (PANACEA)Metabolic SyndromeNetherlands, Spain
-
Organon and CoCompletedMyocardial Infarction | Hypercholesterolemia
-
University of Sao PauloCompletedCoronary Heart Disease
-
Organon and CoCompleted
-
Maha ZuhairCompletedDental Implants , Osseointegration , Marginal Bone Loss , Implant StabilityIraq
-
Organon and CoCompletedHypercholesterolemia
-
Hue University of Medicine and PharmacyUniversità degli Studi di SassariUnknownChronic Kidney Diseases | HypercholesterolemiaVietnam
-
University of Maryland, BaltimoreMerck Sharp & Dohme LLCCompletedMetabolic SyndromeUnited States